Product Code: VMR11218571
The global demand for Gene Expression Analysis Market is presumed to reach the market size of nearly USD 34.39 Billion by 2032 from USD 21.1 Billion in 2023 with a CAGR of 5.58% under the study period 2024-2032.
Gene expression analysis or GEA is the method of extracting data to investigate the behaviour of biological systems. Gene expression analysis combines various steps-transcription, RNA splicing, translation, and post-translational modification of a protein. This process is viewed as a sensitive indicator of biological activity in which a change in gene expression pattern results in the difference in the biological process. GEA has proven to be an effective tool in molecular biology research, which is used to understand the functioning of genes, diagnose diseases, and help in drug development.
MARKET DYNAMICS
The increased need for personalized medicine will likely influence the global gene expression analysis market over the projection timeframe. Besides, increased funding of associated programs is estimated to fuel market growth in upcoming years. Moreover, the rising prevalence of cancer patients globally has led to the rise in demand and application of gene expression analysis. Another significant factor likely to influence the growth of the global gene expression analysis market is the strong emphasis on laboratory research. Drug discovery and development are other factors that are likely to offer lucrative growth opportunities for market growth. Additionally, increased government funding in the direction of genomics has further propelled the market growth rate. However, factors such as lack of skilled labour, lack of awareness and high cost of instruments may hamper the market growth.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Gene Expression Analysis. The growth and trends of Gene Expression Analysis industry provide a holistic approach to this study.
MARKET SEGMENTATION
This section of the Gene Expression Analysis market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Process
- Sample Collection
- Purification
- CDNA synthesis & conversion
- PCR Analysis
- Data analysis & interpretation
By Product
- Kits & Reagents
- DNA Chips
- Others
By Capacity
- Low- to Mid- Plex
- High-Plex
By Application
- Drug Discovery & Development
- Clinical Diagnostics
- Biotech & Microbiology
- Others
By Technique
- RNA Expression
- Promoter Analysis
- Protein Expression & Posttranslational Modification Analysis
- Regional Analysis
This section covers the regional outlook, which accentuates current and future demand for the Gene Expression Analysis market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Gene Expression Analysis market include Qiagen, Quest Diagnostics Inc., F. Hoffmann-La Roche Ltd., Illumina Inc., PerkinElmer Inc., Bio-Rad Laboratories, Thermo Fisher Scientific Inc., Agilent Technologies, GE Healthcare, Promega Corp., Luminex Corp., Takara Bio Inc., Danaher Corp., ELITechGroup, AutoGenomics, Biocartis NV, IntegraGen, Interpace Biosciences Inc., Fluidigm Corp. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
TABLE OF CONTENTS
1. PREFACE
- 1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology
2. EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3. GENE EXPRESSION ANALYSIS - INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porter's Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Process
- 3.7.2 Market Attractiveness Analysis By Product
- 3.7.3 Market Attractiveness Analysis By Capacity
- 3.7.4 Market Attractiveness Analysis By Application
- 3.7.5 Market Attractiveness Analysis By Technique
- 3.7.6 Market Attractiveness Analysis By Region
4. VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend
5. GLOBAL GENE EXPRESSION ANALYSIS MARKET ANALYSIS BY PROCESS
- 5.1. Overview By Process
- 5.2. Historical and Forecast Data Analysis By Process
- 5.3. Sample Collection Historic and Forecast Sales By Regions
- 5.4. Purification Historic and Forecast Sales By Regions
- 5.5. CDNA synthesis & conversion Historic and Forecast Sales By Regions
- 5.6. PCR Analysis Historic and Forecast Sales By Regions
- 5.7. Data analysis & interpretation Historic and Forecast Sales By Regions
6. GLOBAL GENE EXPRESSION ANALYSIS MARKET ANALYSIS BY PRODUCT
- 6.1. Overview By Product
- 6.2. Historical and Forecast Data Analysis By Product
- 6.3. Kits & Reagents Historic and Forecast Sales By Regions
- 6.4. DNA Chips Historic and Forecast Sales By Regions
- 6.5. Others Historic and Forecast Sales By Regions
7. GLOBAL GENE EXPRESSION ANALYSIS MARKET ANALYSIS BY CAPACITY
- 7.1. Overview By Capacity
- 7.2. Historical and Forecast Data Analysis By Capacity
- 7.3. Low- to Mid- Plex Historic and Forecast Sales By Regions
- 7.4. High-Plex Historic and Forecast Sales By Regions
8. GLOBAL GENE EXPRESSION ANALYSIS MARKET ANALYSIS BY APPLICATION
- 8.1. Overview By Application
- 8.2. Historical and Forecast Data Analysis By Application
- 8.3. Drug Discovery & Development Historic and Forecast Sales By Regions
- 8.4. Clinical Diagnostics Historic and Forecast Sales By Regions
- 8.5. Biotech & Microbiology Historic and Forecast Sales By Regions
- 8.6. Others Historic and Forecast Sales By Regions
9. GLOBAL GENE EXPRESSION ANALYSIS MARKET ANALYSIS BY TECHNIQUE
- 9.1. Overview By Technique
- 9.2. Historical and Forecast Data Analysis By Technique
- 9.3. RNA Expression Historic and Forecast Sales By Regions
- 9.4. Promoter Analysis Historic and Forecast Sales By Regions
- 9.5. Protein Expression & Posttranslational Modification Analysis Historic and Forecast Sales By Regions
10. GLOBAL GENE EXPRESSION ANALYSIS MARKET ANALYSIS BY GEOGRAPHY
- 10.1. Regional Outlook
- 10.2. Introduction
- 10.3. North America Sales Analysis
- 10.3.1 Overview, Historic and Forecast Data Sales Analysis
- 10.3.2 North America By Segment Sales Analysis
- 10.3.3 North America By Country Sales Analysis
- 10.3.4 United States Sales Analysis
- 10.3.5 Canada Sales Analysis
- 10.3.6 Mexico Sales Analysis
- 10.4. Europe Sales Analysis
- 10.4.1 Overview, Historic and Forecast Data Sales Analysis
- 10.4.2 Europe By Segment Sales Analysis
- 10.4.3 Europe By Country Sales Analysis
- 10.4.4 United Kingdom Sales Analysis
- 10.4.5 France Sales Analysis
- 10.4.6 Germany Sales Analysis
- 10.4.7 Italy Sales Analysis
- 10.4.8 Russia Sales Analysis
- 10.4.9 Rest Of Europe Sales Analysis
- 10.5. Asia Pacific Sales Analysis
- 10.5.1 Overview, Historic and Forecast Data Sales Analysis
- 10.5.2 Asia Pacific By Segment Sales Analysis
- 10.5.3 Asia Pacific By Country Sales Analysis
- 10.5.4 China Sales Analysis
- 10.5.5 India Sales Analysis
- 10.5.6 Japan Sales Analysis
- 10.5.7 South Korea Sales Analysis
- 10.5.8 Australia Sales Analysis
- 10.5.9 South East Asia Sales Analysis
- 10.5.10 Rest Of Asia Pacific Sales Analysis
- 10.6. Latin America Sales Analysis
- 10.6.1 Overview, Historic and Forecast Data Sales Analysis
- 10.6.2 Latin America By Segment Sales Analysis
- 10.6.3 Latin America By Country Sales Analysis
- 10.6.4 Brazil Sales Analysis
- 10.6.5 Argentina Sales Analysis
- 10.6.6 Peru Sales Analysis
- 10.6.7 Chile Sales Analysis
- 10.6.8 Rest of Latin America Sales Analysis
- 10.7. Middle East & Africa Sales Analysis
- 10.7.1 Overview, Historic and Forecast Data Sales Analysis
- 10.7.2 Middle East & Africa By Segment Sales Analysis
- 10.7.3 Middle East & Africa By Country Sales Analysis
- 10.7.4 Saudi Arabia Sales Analysis
- 10.7.5 UAE Sales Analysis
- 10.7.6 Israel Sales Analysis
- 10.7.7 South Africa Sales Analysis
- 10.7.8 Rest Of Middle East And Africa Sales Analysis
11. COMPETITIVE LANDSCAPE OF THE GENE EXPRESSION ANALYSIS COMPANIES
- 11.1. Gene Expression Analysis Market Competition
- 11.2. Partnership/Collaboration/Agreement
- 11.3. Merger And Acquisitions
- 11.4. New Product Launch
- 11.5. Other Developments
12. COMPANY PROFILES OF GENE EXPRESSION ANALYSIS INDUSTRY
- 12.1. Top Companies Market Share Analysis
- 12.2. Market Concentration Rate
- 12.3. Qiagen
- 12.3.1 Company Overview
- 12.3.2 Company Revenue
- 12.3.3 Products
- 12.3.4 Recent Developments
- 12.4. Quest Diagnostics Inc.
- 12.4.1 Company Overview
- 12.4.2 Company Revenue
- 12.4.3 Products
- 12.4.4 Recent Developments
- 12.5. F. Hoffmann-La Roche Ltd.
- 12.5.1 Company Overview
- 12.5.2 Company Revenue
- 12.5.3 Products
- 12.5.4 Recent Developments
- 12.6. Illumina Inc.
- 12.6.1 Company Overview
- 12.6.2 Company Revenue
- 12.6.3 Products
- 12.6.4 Recent Developments
- 12.7. PerkinElmer Inc.
- 12.7.1 Company Overview
- 12.7.2 Company Revenue
- 12.7.3 Products
- 12.7.4 Recent Developments
- 12.8. Bio-Rad Laboratories
- 12.8.1 Company Overview
- 12.8.2 Company Revenue
- 12.8.3 Products
- 12.8.4 Recent Developments
- 12.9. Thermo Fisher Scientific Inc.
- 12.9.1 Company Overview
- 12.9.2 Company Revenue
- 12.9.3 Products
- 12.9.4 Recent Developments
- 12.10. Agilent Technologies
- 12.10.1 Company Overview
- 12.10.2 Company Revenue
- 12.10.3 Products
- 12.10.4 Recent Developments
- 12.11. GE Healthcare
- 12.11.1 Company Overview
- 12.11.2 Company Revenue
- 12.11.3 Products
- 12.11.4 Recent Developments
- 12.12. Promega Corp.
- 12.12.1 Company Overview
- 12.12.2 Company Revenue
- 12.12.3 Products
- 12.12.4 Recent Developments
- 12.13. Luminex Corp.
- 12.13.1 Company Overview
- 12.13.2 Company Revenue
- 12.13.3 Products
- 12.13.4 Recent Developments
- 12.14. Takara Bio Inc.
- 12.14.1 Company Overview
- 12.14.2 Company Revenue
- 12.14.3 Products
- 12.14.4 Recent Developments
- 12.15. Danaher Corp.
- 12.15.1 Company Overview
- 12.15.2 Company Revenue
- 12.15.3 Products
- 12.15.4 Recent Developments
- 12.16. ELITechGroup
- 12.16.1 Company Overview
- 12.16.2 Company Revenue
- 12.16.3 Products
- 12.16.4 Recent Developments
- 12.17. AutoGenomics
- 12.17.1 Company Overview
- 12.17.2 Company Revenue
- 12.17.3 Products
- 12.17.4 Recent Developments
- 12.18. Biocartis NV
- 12.18.1 Company Overview
- 12.18.2 Company Revenue
- 12.18.3 Products
- 12.18.4 Recent Developments
- 12.19. IntegraGen
- 12.19.1 Company Overview
- 12.19.2 Company Revenue
- 12.19.3 Products
- 12.19.4 Recent Developments
- 12.20. Interpace Biosciences Inc.
- 12.20.1 Company Overview
- 12.20.2 Company Revenue
- 12.20.3 Products
- 12.20.4 Recent Developments
- 12.21. Fluidigm Corp
- 12.21.1 Company Overview
- 12.21.2 Company Revenue
- 12.21.3 Products
- 12.21.4 Recent Developments
Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies